Market Overview:
The global NADPH oxidase 4 market is expected to register a CAGR of xx% during the forecast period 2018-2030. The market growth can be attributed to the increasing prevalence of chronic diseases, rising geriatric population, and technological advancements in the field of diagnostics. Based on type, the global NADPH oxidase 4 market is segmented into GKT-136901, GKT-831, MTfp-siRNA and others. Based on application, the global NADPH oxidase 4 market is segmented into ischemic stroke, kidney disease liver fibrosis and kidney fibrosis among others. Geographically, North America dominates the global NADPH oxidase 4 market followed by Europe and Asia Pacific respectively.
Product Definition:
NADPH Oxidase 4 is an enzyme that helps to produce energy in cells. It is important for the health of cells, and plays a role in many different processes.
GKT-136901:
GKT-136901 is a selective inhibitor of GSK, which has been tested in vitro and in vivo. It has shown to have IC50 values of 19 nM and 10 nM respectively.
GKT-831:
GKT-831 is a selective inhibitor of GSK, which has been studied in combination with PD-1 for the treatment of multiple myeloma and lymphoma. The drug was found to be effective in Phase II clinical trials but failed to progress further due to adverse side effects.
Application Insights:
Ischemic stroke was the leading application segment in 2017 and accounted for a share of over 40.0% in the global market. Increasing prevalence of ischemic stroke and related neurological disorders, such as cerebrovascular disorder, Alzheimer¢â‚¬â„¢s disease, and Parkinson¢â‚¬â„¢s disease will drive the demand for NADPH oxidase 4 inhibitors during the forecast period.
The kidney diseases segment is expected to witness lucrative growth during the forecast period due to an increase in incidence of chronic kidney diseases (CKD). According to U.S Department of Health & Human Services CKD affects more than 30 million people across America alone which includes stage 3 & 4 CKDu which involves loss of Kidney Function Index (KFI) due to reduced glomerular filtration rate (GFR) or kidneys failure.
Regional Analysis:
North America NADPH Oxidase 4 Market accounted for the largest share in 2016 owing to the presence of major pharmaceutical and biopharmaceutical companies, government support, and high healthcare expenditure. The region is expected to maintain its dominance over the forecast period due to increasing R&D activities by various companies. For instance, Pfizer Inc., a U.S.-based company has developed new drugs such as Trobalt that acts on platelet aggregation & clotting pathways which is used for treating hypertension and other coagulation disorders associated with atherosclerosis or stroke caused by blood clots.
Asia Pacific market was valued at USD X million in 2016 owing to growing demand from China & Japan where many large scale clinical trials are being conducted for developing novel therapeutics targeting oxidase enzyme activity levels in patients suffering from kidney diseases such as Fanconi syndrome (FS), minimal change disease (MCD) & diabetic nephropathy (DN).
Growth Factors:
- Increasing prevalence of chronic diseases: The increasing prevalence of chronic diseases is one of the key growth drivers for the NADPH Oxidase 4 market. According to a study by the World Health Organization (WHO), it is estimated that around 36 million people died due to chronic diseases in 2012, and this number is expected to reach 58 million by 2030. This will create a high demand for NADPH Oxidase 4 products and services, thereby driving the market growth.
- Rising geriatric population: The global geriatric population is growing at a rapid pace and this is expected to drive the demand for NADPH Oxidase 4 products and services in the coming years. As per estimates, around 809 million people aged 60 years or above were living worldwide in 2015, which is projected to increase to 1.4 billion by 2050. This will create opportunities for players operating in the NADPH Oxidase 4 market as they focus on catering to this segment’s needs.
Scope Of The Report
Report Attributes
Report Details
Report Title
NADPH Oxidase 4 Market Research Report
By Type
GKT-136901, GKT-831, MTfp-siRNA, Others
By Application
Ischemic Stroke, Kidney Disease, Liver Fibrosis, Kidney Fibrosis, Others
By Companies
Bioasis Technologies Inc, GenKyoTex SA, Glucox Biotech AB, Bioasis Technologies Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
160
Number of Tables & Figures
112
Customization Available
Yes, the report can be customized as per your need.
Global NADPH Oxidase 4 Market Report Segments:
The global NADPH Oxidase 4 market is segmented on the basis of:
Types
GKT-136901, GKT-831, MTfp-siRNA, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Ischemic Stroke, Kidney Disease, Liver Fibrosis, Kidney Fibrosis, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bioasis Technologies Inc
- GenKyoTex SA
- Glucox Biotech AB
- Bioasis Technologies Inc
Highlights of The NADPH Oxidase 4 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- GKT-136901
- GKT-831
- MTfp-siRNA
- Others
- By Application:
- Ischemic Stroke
- Kidney Disease
- Liver Fibrosis
- Kidney Fibrosis
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the NADPH Oxidase 4 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
NADPH Oxidase 4 is an enzyme that catalyzes the oxidation of NADPH to NADP+ in the presence of oxygen. This enzyme is important for the production of energy in cells and plays a role in many biological processes, including DNA replication and photosynthesis.
Some of the major players in the nadph oxidase 4 market are Bioasis Technologies Inc, GenKyoTex SA, Glucox Biotech AB, Bioasis Technologies Inc.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 NADPH Oxidase 4 Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 NADPH Oxidase 4 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 NADPH Oxidase 4 Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the NADPH Oxidase 4 Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global NADPH Oxidase 4 Market Size & Forecast, 2020-2028
4.5.1 NADPH Oxidase 4 Market Size and Y-o-Y Growth
4.5.2 NADPH Oxidase 4 Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 GKT-136901
5.2.2 GKT-831
5.2.3 MTfp-siRNA
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Ischemic Stroke
6.2.2 Kidney Disease
6.2.3 Liver Fibrosis
6.2.4 Kidney Fibrosis
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global NADPH Oxidase 4 Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 NADPH Oxidase 4 Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 GKT-136901
9.6.2 GKT-831
9.6.3 MTfp-siRNA
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Ischemic Stroke
9.10.2 Kidney Disease
9.10.3 Liver Fibrosis
9.10.4 Kidney Fibrosis
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 GKT-136901
10.6.2 GKT-831
10.6.3 MTfp-siRNA
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Ischemic Stroke
10.10.2 Kidney Disease
10.10.3 Liver Fibrosis
10.10.4 Kidney Fibrosis
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 GKT-136901
11.6.2 GKT-831
11.6.3 MTfp-siRNA
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Ischemic Stroke
11.10.2 Kidney Disease
11.10.3 Liver Fibrosis
11.10.4 Kidney Fibrosis
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 GKT-136901
12.6.2 GKT-831
12.6.3 MTfp-siRNA
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Ischemic Stroke
12.10.2 Kidney Disease
12.10.3 Liver Fibrosis
12.10.4 Kidney Fibrosis
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 GKT-136901
13.6.2 GKT-831
13.6.3 MTfp-siRNA
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Ischemic Stroke
13.10.2 Kidney Disease
13.10.3 Liver Fibrosis
13.10.4 Kidney Fibrosis
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 NADPH Oxidase 4 Market: Competitive Dashboard
14.2 Global NADPH Oxidase 4 Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bioasis Technologies Inc
14.3.2 GenKyoTex SA
14.3.3 Glucox Biotech AB
14.3.4 Bioasis Technologies Inc
